Thawing and infusion of CAR-T cell products

Some patients with hematologic malignancies may benefit from chimeric antigen receptor-T (CAR-T) cell treatment. Usually, the manufacture of this cells is carried out by centralized and specialized therapy laboratories that cryopreserve CAR-T in bags send it for infusion patient treatment center. In context, thawing products are critical steps custody chain. This article aims to discuss most relevant points related proposes a kind standard operational protocol (SOP) these processes.